The purpose of this study is to learn if a study medication called semaglutide (known as Ozempic) improves blood sugar control in people treated with dialysis.
If you enroll in the study, you will be randomized to receive semaglutide or placebo (dummy drug). The study is double-blinded, which means neither you nor the researchers will know which you are on. You have a 50% chance of receiving the active drug, semaglutide. Once you are randomized, the study involves taking a shot of the medication every week and monitoring your blood sugars. We will give you all the supplies you need for this study. At certain times during the study, you will wear a continuous glucose monitor, which is a small device that you can wear on your arm or your belly and reads your blood sugar every 5 minutes. The visits will often be by phone, but you will need to come into clinic at least four times during the study.
Up to $480 dollars, Blood sugar monitoring devices, comprehensive diabetes care
UNC Eastowne Medical Office Building
100 Eastowne Dr, Chapel Hill, NC 27514, USA
Klara Klein
Medicine-Endocrinology
Clinical or Medical
Interventional
Chronic Conditions
Diabetes
Kidneys and Liver
Obesity
23-1060